OBJECTIVE: To provide guidelines for future trials, we reviewed the outcomes of children with synchronous bilateral Wilms tumors (BWT) treated on National Wilms Tumor Study-4 (NWTS-4). METHODS: NWTS-4 enrolled 3335 patients including 188 patients with BWT (5.6%). Treatment and outcome data were collected. RESULTS: Among 188 BWT patients registered with NWTS-4, 195 kidneys in 123 patients had initial open biopsy, 44 kidneys in 31 patients had needle biopsies. Although pre-resection chemotherapy was recommended, 87 kidneys in 83 patients were managed with primary resection: Complete nephrectomy 48 in 48 patients, 31 partial/wedge nephrectomies in 27 patients, enucleations 8 in 8 patients. No initial surgery was performed in 45 kidneys in 43 patients, 5 kidneys in 3 patients not coded. Anaplasia was diagnosed after completion of the initial course of chemotherapy in 14 patients (initial surgical procedure: 9 open biopsies, 4 needle biopsies, 1 partial nephrectomy). The average number of days from the start of chemotherapy to diagnosis of anaplasia was 390 (range 44-1925 days). Relapse or progression of disease occurred in 54 children. End stage renal failure occurred in 23 children, 6 of whom had bilateral nephrectomies. The 8 year event free survival for BWT with favorable histology was 74%, and overall survival was 89%; whereas the event free survival for BWT with unfavorable histology was 40%, overall survival was 45%. CONCLUSION: The current analysis of patients with BWT treated on NWTS-4 shows that preservation of renal parenchyma is possible in many patients after initial preoperative chemotherapy. The incidence of end-stage renal disease remains significantly higher in children with BWT. Future studies are warranted to address the need for earlier biopsy in nonresponsive tumors and earlier definitive surgery to recognize unfavorable histology in these high-risk patients.
OBJECTIVE: To provide guidelines for future trials, we reviewed the outcomes of children with synchronous bilateral Wilms tumors (BWT) treated on National Wilms Tumor Study-4 (NWTS-4). METHODS: NWTS-4 enrolled 3335 patients including 188 patients with BWT (5.6%). Treatment and outcome data were collected. RESULTS: Among 188 BWT patients registered with NWTS-4, 195 kidneys in 123 patients had initial open biopsy, 44 kidneys in 31 patients had needle biopsies. Although pre-resection chemotherapy was recommended, 87 kidneys in 83 patients were managed with primary resection: Complete nephrectomy 48 in 48 patients, 31 partial/wedge nephrectomies in 27 patients, enucleations 8 in 8 patients. No initial surgery was performed in 45 kidneys in 43 patients, 5 kidneys in 3 patients not coded. Anaplasia was diagnosed after completion of the initial course of chemotherapy in 14 patients (initial surgical procedure: 9 open biopsies, 4 needle biopsies, 1 partial nephrectomy). The average number of days from the start of chemotherapy to diagnosis of anaplasia was 390 (range 44-1925 days). Relapse or progression of disease occurred in 54 children. End stage renal failure occurred in 23 children, 6 of whom had bilateral nephrectomies. The 8 year event free survival for BWT with favorable histology was 74%, and overall survival was 89%; whereas the event free survival for BWT with unfavorable histology was 40%, overall survival was 45%. CONCLUSION: The current analysis of patients with BWT treated on NWTS-4 shows that preservation of renal parenchyma is possible in many patients after initial preoperative chemotherapy. The incidence of end-stage renal disease remains significantly higher in children with BWT. Future studies are warranted to address the need for earlier biopsy in nonresponsive tumors and earlier definitive surgery to recognize unfavorable histology in these high-risk patients.
Authors: M F Tournade; C Com-Nougué; J de Kraker; R Ludwig; A Rey; J M Burgers; B Sandstedt; J Godzinski; M Carli; R Potter; J M Zucker Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: G J D'Angio; A Evans; N Breslow; B Beckwith; H Bishop; V Farewell; W Goodwin; L Leape; N Palmer; L Sinks; W Sutow; M Tefft; J Wolff Journal: Cancer Date: 1981-05-01 Impact factor: 6.860
Authors: A Weirich; I Leuschner; D Harms; G M Vujanic; J Tröger; U Abel; N Graf; D Schmidt; R Ludwig; P A Voûte Journal: Ann Oncol Date: 2001-03 Impact factor: 32.976
Authors: Andrew M Davidoff; Dana W Giel; Deborah P Jones; Jesse J Jenkins; Matthew J Krasin; Fredric A Hoffer; Mark A Williams; Jeffrey S Dome Journal: Cancer Date: 2008-05-01 Impact factor: 6.860
Authors: Rand N Wilcox Vanden Berg; Emily N Bierman; Megan Van Noord; Henry E Rice; Jonathan C Routh Journal: Urol Oncol Date: 2015-08-05 Impact factor: 3.498
Authors: Rodrigo B Interiano; Noel Delos Santos; Sujuan Huang; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel M Green; Andrew M Davidoff Journal: Cancer Date: 2015-04-01 Impact factor: 6.860
Authors: Marry M van den Heuvel-Eibrink; Janna A Hol; Kathy Pritchard-Jones; Harm van Tinteren; Rhoikos Furtwängler; Arnauld C Verschuur; Gordan M Vujanic; Ivo Leuschner; Jesper Brok; Christian Rübe; Anne M Smets; Geert O Janssens; Jan Godzinski; Gema L Ramírez-Villar; Beatriz de Camargo; Heidi Segers; Paola Collini; Manfred Gessler; Christophe Bergeron; Filippo Spreafico; Norbert Graf Journal: Nat Rev Urol Date: 2017-10-31 Impact factor: 14.432
Authors: Rodrigo B Interiano; M Beth McCarville; Noel Delos Santos; Shenghua Mao; Jianrong Wu; Jeffrey S Dome; Kathleen Kieran; Mark A Williams; Rachel C Brennan; Matthew J Krasin; Daniel M Green; Andrew M Davidoff Journal: J Pediatr Surg Date: 2016-10-27 Impact factor: 2.545
Authors: Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Andrew M Davidoff; Rodrigo B Interiano; Lynn Wynn; Noel Delos Santos; Jeffrey S Dome; Daniel M Green; Rachel C Brennan; M Beth McCarville; Matthew J Krasin; Kathleen Kieran; Mark A Williams Journal: Ann Surg Date: 2015-10 Impact factor: 12.969